TGNA:FRA
Transgene SA
0,67 €
arrow_downward
−0,15%(−0,00100) 1D
13. lis, 22:00:00 GMT+2 · EUR
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za TGNA...
Otvori
0,67 €
Najviša
0,67 €
Najniža
0,67 €
Trž. kap.
192,17 mil.
Prosj. kol.
0,00
Količina
0,00
52-tjed. najviša
1,48 €
52-tjed. najniža
0,60 €
EPS
−0,17 €
Broj djelatnika
152
Otvori
0,67 €
Najviša
0,67 €
Najniža
0,67 €
Trž. kap.
192,17 mil.
Prosj. kol.
0,00
Količina
0,00
52-tjed. najviša
1,48 €
52-tjed. najniža
0,60 €
EPS
−0,17 €
Broj djelatnika
152
Vijesti
Iz web-izvora i od partnera za vijesti
Naslovi.net
·
prije 20 sati
Wall Street: Micron gubitnik dana, samo Dow Jones u plusu
Yahoo Finance
·
prije 1 sat
Dow, S&P 500, Nasdaq Futures Mixed Amid Rising Oil Prices Ahead Of CPI Data: BAC, RIVN, SLS, GME Stocks In Focus
WXXV News 25
·
prije 1 sat
US stocks edge back from their record following the first big batch of profit reports for the summer
HDFC Sky
·
prije 1 sat
US Stocks End Mixed as Chip Selloff Hits Nasdaq
Profil
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
Transgene SA – informacije